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Abstract Despite the introduction of new nucleos(t)ide
analogues in recent years, peginterferon is still recommen-
ded as a potential first-line treatment option by current
practice guidelines for the management of chronic hepatitis
B. Peginterferon offers the advantage of higher sustained
off-treatment response rates compared to nucleos(t)ide
analogues because of its immunomodulatory effects.
Sustained transition to the inactive hepatitis B surface
antigen (HBsAg) carrier state can be achieved in about 30%
of hepatitis B e antigen (HBeAg)–positive patients and 20%
of HBeAg-negative patients. Recent studies have focused
on identification of pretreatment and on-treatment factors
that allow the selection of patients who are likely to achieve
a sustained response to peginterferon therapy in order to
avoid the side-effects and costs associated with unnecessary
treatment. Future studies need to address whether specific
virologic benchmarks can guide individualized decisions
concerning therapy continuation and whether peginterferon
combined with new potent nucleos(t)ide analogues
improves treatment outcomes.
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Introduction
Chronic hepatitis B (CHB) is one of the most serious and
prevalent infectious diseases worldwide. It is estimated
that about one third of the world’s population has
evidence of infection, current or remote, with the
hepatitis B virus (HBV). Although safe and effective
vaccines have been available for more than two decades,
more than 350 million people worldwide are chronically
infected with HBV [1]. Progression of HBV-related liver
disease to cirrhosis, hepatic decompensation, and hepato-
cellular carcinoma (HCC) is estimated to result in 0.5 to
1.2 million deaths annually [1]. The dual immunomodu-
latory and antiviral agent interferon (IFN)-α has been a
mainstay in the treatment of CHB since it was licensed for
this indication in the early 1990s. Since 1998, consider-
able progress has been made in the treatment of CHB with
the introduction of nucleos(t)ide analogues (NA), which
directly inhibit HBV polymerase and provide, at least in
the short term, a well-tolerated and effective alternative to
IFN therapy [2]. IFN-based therapy also improved
significantly by pegylation of IFN, which allowed a more
convenient once-weekly dosing interval, with treatment
efficacy equal or superior to conventional IFN [3].
Currently, IFN (conventional or pegylated [PEG]) and
five NA (lamivudine, telbivudine, adefovir, entecavir, and
tenofovir) have been approved for the treatment of CHB in
many parts of the world. Along with the introduction of
these agents, the complexity of antiviral therapy for CHB
has increased, leading to the development of multiple
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international practice guidelines in recent years [4, 5]. All
guidelines recommend both PEG-IFN and NA as initial
treatment options, but the optimal choice for individual
patients remains controversial. In this article, we review
the role of IFN in CHB therapy.
Indications for Treatment
Phases of Chronic Hepatitis B
Patients with CHB may present in one of four phases [4, 5].
During the immunotolerant phase, hepatitis B e antigen
(HBeAg) is detectable and serum HBV DNA is high, but
serum alanine aminotransferase (ALT) levels are normal and
liver histology shows minimal inflammation. This phase may
last between 1 and 4 decades, but it can be much shorter or
absent if the infection is acquired later in life. During the
immunoactive phase, HBeAg remains detectable, but the host
immune response against the virus results in a decline in
serum HBV DNA and hepatic inflammation. Activation of the
host immune response can result in HBeAg loss and
seroconversion to anti-HBe. HBeAg seroconversion is usually
followed by the immune-control phase (inactive hepatitis B
surface antigen [HBsAg] carrier state), characterized by a low
serum HBV DNA level and minimal hepatic inflammation.
However, in a significant proportion of HBeAg-negative
patients, viral replication recurs or persists at high levels,
resulting in HBeAg-negative active CHB. This phase of
the infection develops spontaneously through mutations in the
precore or basal core promoter region that reduce the
expression of HBeAg [6].
Practice Guidelines
In general, treatment is recommended for patients with high
serum HBV DNA and elevated ALT levels, indicating the
active host immune response against HBV. The 2009
American Association for the Study of Liver Diseases
(AASLD) guidelines advocate antiviral treatment for patients
who remain HBeAg positive with serum HBV DNA levels
greater than 20,000 IU/mL combined with persistently
elevated ALT levels (greater than 2 times the upper limit of
normal [ULN] over a 3–6 month period) [5]. The same HBV
DNA and ALT criteria apply to HBeAg-negative patients,
but these patients should also be considered for treatment if
the HBV DNA concentration is greater than 2,000 IU/mL
combined with a liver biopsy showing moderate to severe
necroinflammation and/or fibrosis [5]. Indications for treat-
ment are the same for HBeAg-positive and HBeAg-negative
patients according to the current HBV guidelines of the
European Association for the Study of the Liver (EASL) [4].
Antiviral therapy should be considered if HBV DNA levels
exceed 2,000 IU/mL, ALT levels are greater than 1 time
ULN, and if a liver biopsy shows moderate to severe
necroinflammation and/or fibrosis [4].
Goals of Antiviral Therapy
The ideal outcome of treatment for any chronic infection is
eradication of the infectious agent. Unfortunately, complete
eradication of HBV is scarcely achieved with the currently
available treatment options for CHB, because covalently
closed circular DNA (cccDNA) persists in host hepatocytes
[7]. Therefore, antiviral therapy aims at the prevention of
cirrhosis, hepatic decompensation, and HCC [8]. Because
these adverse clinical events develop only after decades of
infection, clinical studies have focused on varying short-
term, surrogate outcomes to assess treatment efficacy [5, 8].
HBeAg seroconversion is frequently used as a primary
endpoint in HBeAg-positive patients treated with PEG-IFN.
Most patients enter an inactive carrier state after achieving
HBeAg seroconversion, characterized by low or undetect-
able HBV DNA levels and normalization of ALT levels.
Long-term follow-up studies have demonstrated that HBeAg
seroconversion is associated with increased survival and a
reduced risk of developing HCC [9–11]. HBeAg serocon-
version is by definition not possible in HBeAg-negative
patients. Thus, suppression of HBV DNA to low or
undetectable levels in combination with normalization of
ALT is considered the most important treatment goal. The
level of HBV DNA applied to define response to therapy
differs between PEG-IFN and NA therapy because their
modes of action differ. The main goal of PEG-IFN therapy is
to achieve sustained immunologic control over the virus,
whereas therapy-maintained suppression of HBV DNA to
undetectable levels is required during NA therapy to prevent
the emergence of antiviral resistance [2]. Response to
PEG-IFN therapy is defined by the sustained presence of
an HBV DNA level below 2,000 IU/mL according to the
European guidelines [4]. Large population studies have
demonstrated that HBsAg-positive patients with an HBV
DNA concentration below this level of viral replication have
a reduced risk of progression to cirrhosis and HCC [9, 12,
13]. Finally, serum HBsAg loss comes as close to clinical
cure as one can expect to achieve in CHB and is clearly
associated with improved outcomes, provided that HBsAg
clearance occurs before the development of cirrhosis [14].
Interferon-α
IFNs were first recognized in 1957 for their ability to
interfere with viral activity. IFNs are naturally occurring
cytokines with immunomodulatory, antiproliferative, and
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antiviral properties. Multiple naturally occurring forms of
IFN exist, including IFN-α produced by lymphocytes [15].
The effects of IFN-α are predominantly immunomodulatory,
although this cytokine also exerts a limited direct antiviral
effect on HBV. IFN-α binds to its cellular receptor and
activates secondary messengers, resulting in the production
of multiple proteins that are important for the defense of the
cell against viruses. Immunomodulatory effects of IFN-α
include enhancement of antigen presentation to the immune
system, activation of natural killer (NK) cells and other
immune cells, and increased production of cytokines.
Antiviral effects include degradation of viral mRNA,
inhibition of viral protein synthesis, and prevention of
infection of cells.
Modification of IFN through the attachment of a polyethylene
glycol (PEG) molecule led to improved pharmacokinetic and
pharmacodynamic properties and has largely replaced conven-
tional IFN. PEG-IFN is administered once weekly, resulting in a
relatively continuous drug exposure during the dosing interval.
Two types of PEG-IFN have been developed: a small linear 12-
kDa PEG, linked to IFN α-2b (PEG-IFN α-2b), and a large
branched 40-kDa PEG, linked to IFN α-2a (PEG-IFN α-2a)
[16]. These molecules have different characteristics due to their
difference in size and structure. PEG-IFN α-2a has a longer
half-life (about 80 h), is mainly catabolized in the liver, and has
active metabolites. PEG-IFN α-2b is smaller and has a shorter
half-life (about 40 h) and may act as a pro-drug depot, slowly
releasing IFN [16]. Both types of PEG-IFN were initially
investigated for the treatment of chronic hepatitis C. Response
rates were superior compared to conventional IFN with a
comparable tolerability profile [16]. PEG-IFN α-2a is registered
for the treatment of both HBeAg-positive and HBeAg-negative
CHB as a 48-week course, in a dosage of 180 μg administered
subcutaneously once a week. PEG-IFN α-2b has only been
registered for the treatment of CHB in countries with a high
prevalence of HBV infection.
Interferon-Based Therapy for HBeAg-Positive Chronic
Hepatitis B
Response Rates
A meta-analysis showed that a higher percentage of IFN-
treated HBeAg-positive patients developed a virologic
response compared to untreated patients [17]. Sustained
clearance of HBeAg and HBV DNAwas achieved in about
one third of patients by 3 to 6 months after discontinuation
of treatment. Furthermore, HBsAg loss was observed more
often in patients treated with IFN [17]. Pegylation of IFN
allowed a more convenient once-weekly dosing interval.
PEG-IFN (180 μg, once weekly) resulted in a larger decline
in HBV DNA levels and a higher rate of HBeAg
seroconversion after 24 weeks of follow-up (33% vs 25%)
compared to standard IFN α-2a (4.5 million units, three
times weekly) [3].
The use of PEG-IFN α-2a and PEG-IFN α-2b for HBeAg-
positive CHB was evaluated in two pivotal trials (Table 1)
[18, 19]. PEG-IFN monotherapy administered for 1 year
resulted in HBeAg seroconversion in about one third of
HBeAg-positive patients after 24 to 26 weeks of treatment-
free follow-up. Sustained viral suppression (serum HBV
DNA < 100,000 to 200,000 copies/mL) occurred in 27% to
32% of patients. Serum HBV DNA was suppressed below
400 copies/mL in 7% to 14% of patients after 6 months of
follow-up. In both studies, PEG-IFN monotherapy was
compared to PEG-IFN and lamivudine (LAM) combination
therapy. Although the latter was associated with more potent
viral suppression during the treatment phase, combination
therapy did not lead to higher sustained response rates [18,
19]. At 6 months after discontinuation of PEG-IFN therapy,
HBsAg seroconversion was observed in 3% to 5% of
HBeAg-positive patients (Table 1).
We recently reported long-term follow-up (mean duration
3 years) results in 172 patients treated with PEG-IFN α-2b
with or without LAM [20••]. Among initial responders
(defined as HBeAg negativity at 26 weeks posttreatment),
HBeAg clearance was sustained in 81% of cases and HBsAg
loss increased to 30%. Overall, HBsAg became negative in
11% of patients at the last visit [20••].
Predictors of Response at Baseline
Because treatment with PEG-IFN is expensive and is
associated with considerable side-effects, identification of
baseline parameters associated with the chance of achieving
sustained response has gained attention recently, particularly
Table 1 Rates of sustained virologic and biochemical response to
PEG-IFN in HBeAg-positive chronic hepatitis Ba
Response after
24–26 weeks of
follow-up
PEG-IFN α-2a
duration of treatment,
48 wk (N=271)
PEG-IFN α-2b
duration of treatment,
52 wk (N=136)
HBV DNA <105 copies/mL 32% 27%
HBV DNA <400 copies/mL 14% 7%
HBeAg clearance 34% 36%
HBeAg seroconversion 32% 29%
HBsAg clearance 3% 7%
HBsAg seroconversion 3% 5%
ALT normalization 41% 32%
a Different assays were used for quantification of HBV DNA in these studies
ALT alanine aminotransferase; HBeAg hepatitis B e antigen; HBsAg
hepatitis B surface antigen; HBV hepatitis B virus; PEG-IFN
pegylated interferon
(Data from Janssen et al. [18] and Lau et al. [19])
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concerning HBV genotype. HBV is currently classified into
eight genotypes (A to H). HBV genotypes A and D are most
common in Europe and North America, while genotypes B
and C are predominant in Asia [21]. Genotype A was found
to be associated with higher rates of sustained response to
conventional IFN compared with genotype D [22]. Further-
more, a higher rate of IFN-induced HBeAg clearance was
observed among genotype B infected patients compared with
genotype C [23].
The importance of genotypes concerning responsiveness to
IFN-based therapy was further emphasized in our study that
pooled data from two pivotal trials investigating the efficacy
of PEG-IFN in HBeAg-positive CHB [24••]. HBV genotype
A, high baseline ALT, low baseline HBV DNA, female sex,
and older age were predictive of a sustained response
(defined as HBeAg loss and HBV DNA < 2,000 IU/mL
6 months after treatment) using univariate analysis. Next, we
constructed a multivariable model allowing prediction of
sustained response to PEG-IFN for individual patients with
the use of readily available baseline parameters. (An
automated calculator is available at www.liver-gi.nl/peg-
ifn). Figure 1 shows average chances of sustained response
based on the presence of low (<2×ULN) or high (≥2×ULN)
ALT levels, and low (<9 log10 copies/mL [<2×10
8 IU/mL])
or high (≥9 log10 copies/mL [≥2.0×108 IU/mL]) HBV DNA
levels for each genotype. General recommendations on
whether to consider PEG-IFN therapy for individual patients
based on a predicted probability of response above 30% are
shown in Table 2.
The durability of response to PEG-IFN therapy may also
be influenced by HBV genotype. Genotype A infected
patients, who lost HBeAg at 26 weeks after treatment with
PEG-IFN α-2b, more often remained negative for HBeAg
compared to those infected with other genotypes at the end
of 3 years of follow-up (96% vs 76%, P=0.06). Further-
more, the rate of HBsAg loss was markedly higher in
genotype A infected patients losing HBeAg at 26 weeks
after treatment compared to patients infected with geno-
types B, C, and D (58% vs 6%, P<0.001) [20••].
On-Treatment Predictors of Response
Despite the availability of baseline predictors of response,
considerable uncertainty remains as to whether an individual
patient will benefit from PEG-IFN therapy. In the manage-
ment of chronic hepatitis C virus (HCV) infection, stopping
rules are used according to the magnitude and rapidity of
HCV RNA decline. On-treatment monitoring of virologic
factors may further improve prediction of response in the
treatment of CHB as well. Frequent monitoring of HBVDNA
levels during treatment has been established as a tool in the
management of CHB [4, 5]. However, the benefit of
monitoring the viral load during treatment with PEG-IFN is
probably limited. Different patterns of viral decline during
PEG-IFN α-2b treatment for HBeAg-positive CHB have
been described. Prediction of response based on viral decline
during the first months of therapy was difficult, because a
considerable response was observed, even in patients with a
late or posttreatment decline of HBV DNA [25]. However,
a recent study showed that addition of on-treatment HBV
Fig. 1 Average predicted chances
of sustained response for HBV
genotypes A to D based on the
presence of low (<2 × ULN) or
high (≥2 × ULN) ALT levels, and
low (<9 log10 copies/mL) or high
(≥9 log10 copies/mL) HBV-DNA
levels. Low < 20%; moderate =
20% to 30%; high ≥ 30% chance
of sustained response.
ALT—alanine aminotransferase;
HBV—hepatitis B virus;
ULN—upper limit of normal
Table 2 General recommendations for the use of PEG-IFN as first-
line therapy for HBeAg-positive chronic hepatitis B
HBV genotype General recommendation
A Either high (≥2 × ULN) ALT or low (<9 log10 cp/mL)
HBV DNA levels
B and C Both high (≥2 × ULN) ALT and low (<9 log10 cp/mL)
HBV DNA levels
D PEG-IFN therapy is not recommended
ALT alanine aminotransferase; HBeAg hepatitis B e antigen; HBV
hepatitis B virus; PEG-IFN pegylated interferon; ULN upper limit of
normal
(Data from Buster et al. [24••])
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DNA decline to the previously described prediction model
improves prediction of sustained response, and it was
recommended to discontinue therapy in patients in whom an
HBVDNA decline of 2 log10 at week 24 is not achieved [26].
In parallel with HBV DNA, quantitative assays for
HBeAg and HBsAg have become available [27]. Fried et
al. [28•] showed that monitoring serum HBeAg levels
during PEG-IFN α-2a treatment may help to predict the
probability of subsequent HBeAg loss or seroconversion.
At 24 weeks of PEG-IFN α-2a therapy, high HBeAg levels
had a greater negative predictive value (96%) compared
with HBV DNA levels at the same time point (86%) [28•].
Serum HBsAg levels probably reflect intrahepatic cccDNA,
the key replicative intermediate [29]. On-treatment reduc-
tion of HBsAg may reflect the immunomodulatory effects
of IFN-based therapy resulting in reduced intrahepatic
cccDNA concentrations [29, 30]. Indeed, responders to
PEG-IFN therapy experience a steeper decline in HBsAg
levels compared to nonresponders. Preliminary results from
the PEG-IFN α-2a trial have indicated that the level of
HBsAg at week 12 was associated with HBeAg serocon-
version at 6 months posttreatment. Patients with HBsAg
levels below 1,500 IU/mL at week 12 had 51% chance of
response, in contrast to only 16% of patients with HBsAg
levels greater than 20,000 IU/mL [31]. However, it is
difficult to establish a clinically useful stopping-rule based
on this study, because a substantial number of future
responders would be lost if all patients with HBsAg levels
exceeding 20,000 IU/mL would discontinue therapy at
week 24. Therefore, additional studies on HBeAg and
HBsAg quantification are needed to validate these assays
before they can be of true predictive value during PEG-IFN
treatment for HBeAg-positive CHB.
Interferon-Based Therapy for HBeAg-Negative Chronic
Hepatitis B
Response Rates
In older studies, patients with HBeAg-negative CHB
responded well to conventional IFN. A treatment course
of 3 to 6 months resulted in an end-of-treatment response
in many patients [32]. However, response was not durable
in a large proportion of these patients, and relapse
occurred in about half of initial responders after treatment
discontinuation [32].
PEG-IFN treatment has been less extensively studied in
HBeAg-negative patients. In one large trial, PEG-IFN α-2a
monotherapy for 48 weeks resulted in a combined response
(HBV DNA < 20,000 copies/mL and normalization of
ALT) in 36% of patients at 24 weeks after treatment
discontinuation [33]. A serum HBV DNA level less than
400 copies/mL was observed in 19% of patients. Six
months after treatment discontinuation, 4% of HBeAg-
negative patients had cleared HBsAg. In parallel with
HBeAg-positive disease, addition of LAM to PEG-IFN
improved end-of-treatment response rates, but this difference
was not sustained posttreatment [33].
Results of long-term follow-up studies have shown
that the off-treatment sustainability of response to
PEG-IFN is lower in HBeAg-negative compared with
HBeAg-positive disease. At 3 years after discontinuation
of PEG-IFN α-2a therapy, a sustained virologic response
(HBV DNA < 10,000 copies/mL at 6 months after
treatment discontinuation) proved to be durable in 43%
of the initial responders. The rate of HBsAg loss
increased to 9% [34••].
Predictors of Response at Baseline
It is a major challenge to identify HBeAg-negative patients
who are likely to benefit from PEG-IFN therapy before
treatment is initiated or as early as possible during the
treatment course. Unfortunately, baseline predictors of
response to PEG-IFN are poorly defined in comparison
with HBeAg-positive disease. A post-hoc analysis of the
study investigating the efficacy of PEG-IFN α-2a for
HBeAg-negative CHB reported that lower baseline serum
HBV DNA levels, higher ALT levels, younger age, female
gender, and HBV genotype B and C (compared to D) were
significantly associated with higher sustained response rates
[35]. However, the clinical usefulness of these predictors is
limited when considering individual patients for PEG-IFN
therapy.
On-Treatment Predictors of Response
Because baseline predictors of response to PEG-IFN are poorly
defined in HBeAg-negative patients, recent studies have
focused on the identification of markers allowing on-
treatment prediction of response. Previous reports indicated
that prediction of response to PEG-IFN by means of serum
HBV DNA levels is difficult [36]. Besides HBV DNA,
HBsAg is the only viral marker that remains detectable in
the serum of CHB patients who become HBeAg negative. A
retrospective study in HBeAg-negative patients treated with
PEG-IFN α-2a showed that an end-of-treatment HBsAg level
below 10 IU/mL and an on-treatment decline greater than
1 log10 IU/mL were significantly associated with sustained
HBsAg clearance 3 years after treatment [37•]. These results
suggest HBsAg decline during PEG-IFN therapy may allow
discrimination between future responders and nonresponders.
In a cohort of 48 patients treated with PEG-IFN α-2a for
48 weeks, high predictive values for on-treatment HBsAg
declines at weeks 12 and 24 on sustained virologic response
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(HBV DNA below 70 copies/mL) were reported [38]. Patients
with more than 0.5 log10 IU/mL HBsAg decline at week 12
had an 89% probability of response, whereas those who did
not achieve this amount of HBsAg decline had a 90% chance
of nonresponse. In contrast, we recently reported that on-
treatment HBsAg decline at week 12 alone was of limited
value in predicting sustained response (HBV DNA < 10,000
copies/mL [≈2,000 IU/mL] and normal ALT at 24 weeks after
treatment discontinuation) in 107 patients treated with
PEG-IFN α-2a (with or without ribavirin) for 48 weeks in a
randomized controlled trial. However, through a combination
of HBsAg and HBV DNA declines at week 12, we were able
to establish a solid stopping rule. None of the 20 patients
(20% of the study population) in whom a decrease in serum
HBsAg level was absent and HBV DNA declined less than
2 log10 copies/mL achieved a sustained response (negative
predictive value 100%) [39].
Potential Treatment Strategies
Combination Therapy
Combination therapy theoretically offers advantages compared
tomonotherapy, including a combination of immunomodulatory
and antiviral effects, synergistic antiviral effects, and a higher
barrier toward resistance. Several studies have assessed whether
the addition of a first generation NA to PEG-IFN therapy
improves treatment outcomes. Irrespective of HBeAg status, the
addition of LAM to PEG-IFN resulted in a higher degree of on-
treatment viral suppression, but similar sustained off-treatment
response compared to PEG-IFN alone [18, 19, 33]. PEG-IFN
α-2b and adefovir (ADV) combination therapy resulted in rates
of HBeAg loss and seroconversion similar to those found in
individuals treated with PEG-IFN alone or in combination with
LAM [30]. Furthermore, no differences in sustained virologic
and biochemical response rates were observed between
HBeAg-negative patients treated with PEG-IFN α-2a mono-
therapy and PEG-IFN and ADV combination therapy [40]. We
recently reported that combining PEG-IFN α-2a with the
immunomodulatory agent ribavirin (RBV) did not lead to
higher response rates for the treatment of HBeAg-negative
patients, compared with PEG-IFN monotherapy [41].
Lowering the viral load before initiating PEG-IFN
therapy may increase response rates, given the association
of lower baseline HBV DNA levels with a higher
probability of response; however, results have been
conflicting [42, 43].
Duration of Treatment
Conventional IFN was typically given for 12 to 24 weeks in
HBeAg-positive patients. One could therefore question
whether PEG-IFN could be given for less than 48 weeks, as
is currently recommended by the manufacturer. Response
rates to 24 weeks of PEG-IFN α-2a in HBeAg-positive CHB
appear to be in the range of those in other studies with longer
treatment duration, but comparison of these results must be
undertaken with caution because patient populations and
PEG-IFN doses differed between studies [3, 18, 19].
Studies using conventional IFN suggested the risk of
relapse after treatment discontinuation may be diminished
with extended treatment in HBeAg-negative patients [44].
A recent study confirmed that 2 years of PEG-IFN α-2a
therapy significantly increased the rate of sustained response
(HBV DNA ≤ 2,000 IU/mL at 1 year after treatment
discontinuation) in genotype D infected HBeAg-negative
patients compared with the currently recommended duration
of 1 year (31% vs 10%, P=0.01) [45].
Side-Effects of Interferon-Based Therapy
In contrast to the well-tolerated NA, IFN-based therapy is
often complicated by the occurrence of side effects. Flu-like
syndrome, headache, myalgia, fatigue, and local reaction at
the injection site are reported most frequently, but do not
require discontinuation of therapy in most cases [18, 19, 33,
46]. Other clinically relevant side effects, including anorexia,
thyroid dysfunction, and hepatitis flares, occur less frequent-
ly. Furthermore, neuropsychiatric symptoms (depression,
agitation, sleeping disturbances) are a major concern.
PEG-IFN has myelosuppressive effects, but clinically
relevant neutropenia or thrombopenia are infrequently
observed, except in patients with cirrhosis who have
decreased cell counts before starting therapy [46].
Although PEG-IFN α-2b in HBeAg-positive patients
with advanced fibrosis but compensated liver disease
proved to be well tolerated and effective [47], decom-
pensated liver disease remains an absolute contraindication
for PEG-IFN treatment because of the risk of IFN-induced
hepatitis flares resulting in hepatic decompensation
[48]. Other important contraindications include severe
psychiatric disorders (depression and suicidal ideation),
severe cardiac disease, and autoimmune hepatitis (or other
autoimmune disorders).
Discussion
Current treatment options for CHB consist of five NA and
PEG-IFN [1]. Both treatment modalities are effective and
can improve long-term outcome. To select the optimal
first-line drug, the advantages and limitations of each agent
as well as patient-specific characteristics should be taken
into account. NA therapy offers oral administration and
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newly registered NA are able to maintain suppression of
viral replication in most patients for prolonged periods.
However, it is uncertain whether oral antiviral therapy can
be discontinued, thus necessitating indefinite therapy in
many patients [49, 50]. Although NA are well tolerated,
extended therapy poses a risk for antiviral resistance and
long-term safety is currently unknown [2]. PEG-IFN
therapy offers the advantage of higher sustained response
rates compared to NA because of its immunomodulatory
effects [20••, 34••]. However, PEG-IFN should only be
considered for patients who are likely to respond to therapy
because of the costs and side-effects associated with this
agent. For HBeAg-positive CHB, a prediction model is
available that provides good discrimination between
responders and nonresponders using readily available
baseline parameters (www.liver-gi.nl/peg-ifn) [24••].
Furthermore, on-treatment monitoring of HBV DNA,
HBeAg, and HBsAg levels may further tailor therapy for
individual patients [26, 28•, 31]. Baseline predictors of
response are poorly defined in HBeAg-negative disease, but
recent results on HBsAg quantification during PEG-IFN
therapy are promising [37•, 38, 39].
Combining immunomodulators with an antiviral agent
theoretically offers advantages, but the addition of LAM,
ADV, and RBV to PEG-IFN therapy did not result in higher
sustained response rates [18, 19, 33, 40, 41]. Combination of
PEG-IFN with more potent antiviral agents (entecavir
[ETV], tenofovir [TDF]), lowering HBV DNA by NA
therapy before commencing PEG-IFN therapy, or prolonging
PEG-IFN therapy may improve treatment outcomes [42, 44].
Conclusions
IFN therapy has been used for to treat CHB for many years.
The availability of new, well-tolerated NA has expanded
treatment options, but sustained off-treatment viral suppres-
sion is yet achieved only in a minority of patients,
necessitating indefinite treatment in most instances. Although
resistance rates appear to be low for ETVand TDF, long-term
resistance and safety data are lacking. The antiviral potency of
PEG-IFN is lower compared to NA and the occurrence of side
effects is an important concern, but response is more durable
in most patients because of its immunomodulatory effects.
PEG-IFN therapy therefore should be considered for patients
without contraindications and with a high likelihood of
response.
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